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ABSTRACT
Background and Purpose: Pediatric cancers affect over ten thousand children in the
United States each year. Although survival rates continue to climb, debilitating long-term
side effects from cancer treatment are surfacing. The purpose of this study was to
investigate the effects of chemotherapy on selected gait characteristics in children ages
five to twenty-two.
Methods: This was a prospective, cross-sectional study that investigated the differences
found in and between children undergoing cancer treatment for non-central nervous
system cancers and children without cancer. The data was collected in the oncology
program of the two campuses of Children’s Hospitals and Clinics of Minnesota. Sixty
children with cancer and thirty-six children without cancer (controls) participated in this
study. Each participant completed impairment testing including: ankle range of motion,
ankle strength, and neuropathy rating using the ped-mTNS. Their gait pattern was
recorded using the GaitRite Gait Analysis System and then each subject completed a 6
minute walk test.
Results: Using MANOVA procedures, we found that subjects with cancer demonstrated
significantly slower walking velocity, decreased cadence, and shorter step length (α≤.05)
compared to controls. No significant gait differences were found between cancer patients
who received vincristine and those who received IT methotrexate in addition to
vincristine (α≥.05). Within the cancer group, significant correlations were found between
underlying impairments of ankle dorsiflexion strength, and neuropathy with
selected gait characteristics (α≤.05). Significant correlations were also found between
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the distance walked in six minutes with velocity and step length (α≤.05).
Conclusions: Children who received chemotherapy treatment had significantly slower
velocities, decreased cadence and shorter step lengths when compared to controls.
However, adding IT methotrexate in addition to vincristine did not significantly impact
gait characteristics. Underlying impairments, such as ankle strength, significantly
affected gait characteristics. Finally, the distance children with cancer walked in six
minutes was negatively impacted by their decreased velocity and step length. Overall,
this study gives insight into the debilitating effects chemotherapy has on selected gait
characteristics. Physical therapy may benefit this population by working to improve gait
patterns and overall function.
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Chapter I: INTRODUCTION
Pediatric cancers, although rare, still affect over ten thousand children in the
United States each year. Healthcare has extensively progressed and survival rates
continue to improve, but cancer is still the second leading cause of death in children
under the age of fifteen.1 Today, children that become cancer survivors exceed 80% of
the pediatric cancer population. These children will very likely become long-term
survivors and will have to learn to live with the inevitable side effects following
treatment.2
Although chemotherapeutic drugs have been successful in treating pediatric
cancers and an increase in cure rates has been seen, the side effects of treatment may be
extensive and debilitating.3,4 Many body systems are adversely affected by such drugs,
including the cardiovascular, pulmonary and sensory systems.
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Chapter II: REVIEW OF RELEVANT RESEARCH
Chemotherapeutic Agent Side Effects:
Chemotherapeutic drugs are designed to destroy rapidly dividing cells; however,
at this time these drugs are not specific enough to target only cancerous cells.
Unfortunately, other healthy cells in the body that also divide rapidly are affected as well.
For example, healthy rapidly dividing cells are found in the endothelial layer of the
gastrointestinal tract, in the blood, and in lymph nodes. Chemotherapeutic agents involve
adverse gastrointestinal effects, immunity suppression, and low production of red and
white blood cells and platelets.
Although neurons in the peripheral nervous system are not rapidly dividing cells,
they can be negatively affected by chemotherapeutic drugs. Sensory and autonomic
neurons and the cells that support them are nourished by highly permeable capillaries that
allow for easy diffusion of toxins.5 Chemotherapy drugs alter axonal transport and also
hinder the metabolic needs of neurons, thus leading to impaired motor and sensory
function.5
Two such drugs utilized in chemotherapy for the treatment of common childhood
cancers are methotrexate (MTX) and vincristine(VCR). MTX is widely used to treat
leukemias and solid tumors in children, and is known to lead to neurotoxicity of the
central nervous system when administered intrathecally or in conjunction with radiation
therapy.5 The side effects of central neurotoxicity may also have a part in contributing to
overall neurotoxicity.6 VCR in conjunction with other agents has been effective in
treating many children with cancer in the United States.7 However, this treatment has
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multiple toxic side effects which limit the dosage at which it can be administered. These
effects often present as peripheral neuropathy, with progressive involvement of motor,
sensory, and autonomic systems.7 The symptoms that accompany the neurotoxic side
effects are pain, numbness and tingling of the hands and feet, and weakness in both upper
and lower extremities.8,5 Within the first five months of treatment, children are at risk of
developing weakness and experiencing a decrease in functional mobility.6 Other long
term impairments include slowed motor nerve conduction velocity, diminished or absent
deep tendon reflexes, decreased ankle range of motion, further weakness in distal
musculature, which have a negative impact on functional mobility.9,5
To date, there are studies that demonstrate that children treated with VCR and
MXT perform significantly poorer on functional outcome measures for playing activities
and mobility when compared to healthy children.10 Research has also indicated decreased
walking efficiency in adult survivors of pediatric cancer.9 However, the impact of
neurotoxic chemotherapy on neuromuscular gait characteristics in children and
adolescents undergoing treatment has yet to be described.

Gait Analysis in Children:
There has been a variety of research, as described above, regarding the effects of
chemotherapy on many different aspects of function. However, limited research has been
conducted connecting these effects to changes in pediatric gait patterns. There are a
variety of techniques used to measure temporal and spatial gait characteristics that have
the potential to change with chemotherapy treatment.
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Visual observation and video analysis with a stopwatch are two inexpensive
techniques to measure gait characteristics with moderate to high reliability, but only
determine temporal gait characteristics. Paper walkway is a technique used to measure
temporal characteristics through visual observation and some aspects of spatial
characteristics from footprints on the paper. Although this method can be used to measure
both temporal and spatial aspects of gait, it can be time consuming to set up and analyze
data. In more recent years, the GaitRite system was developed as a simplified data
collection system for temporal and spatial gait analysis. This system uses a flat walkway
with multiple pressure sensors, which record a variety of gait characteristics on a
computer. Several research studies have focused on determining the validity and
reliability of the GaitRite system with a wide variety of subjects ranging from children to
adults and healthy to impaired subjects. Overall, high validity and reliability have been
established for this system.11,12
The GaitRite system has also been utilized to analyze pediatric and adult gait
patterns in populations that present with impaired gait. These studies obtained normative
and impaired temporal-spatial gait characteristics in children, young adults, and adults
using the GaitRite walkway system, which has been reported to have moderate to high
validity and reliability. The data obtained is able to be utilized as a comparison for future
studies and is beneficial in recognizing pathologic gait characteristics.13,14,15,16 For these
reasons the GaitRite system was chosen for gait data collection of the present study.
The purpose of this study was to investigate the effects of chemotherapy on
selected gait characteristics in children and adolescents ages five to twenty-two years.
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This study is part of a larger, on-going study of the impact of chemotherapy on physical
function in school-aged children and adolescents.
We generated multiple hypotheses based on the available literature for this study:
1. The gait characteristics of children/adolescents with cancer will differ from
children/adolescents without cancer.
2. The gait characteristics of subjects treated with different types of chemotherapy (that
is vincristine vs. vincristine with MTX) will be similar.
3. Select neuromuscular impairments will be significantly related to changes observed in
the gait pattern of children/adolescents with cancer.
4. Children/adolescents without cancer will walk farther in six minutes compared to
children/adolescents with cancer.
5. Selected gait characteristics will be significantly related to the distance subjects
walked in six minutes.
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Chapter III: METHODS
Study Design
The study had a prospective and cross-sectional design that used a descriptive
technique to analyze gait characteristics and is quasi-experimental in estimating the
impacts of chemotherapy on selected gait characteristics. All the data collected for each
participant was completed in one day and included a chart review or health history and
impairment, gait, and functional measurements.

Subjects
Participants were recruited through the oncology program at the two campuses of
the Children’s Hospitals and Clinics of Minnesota. Subjects and their parents were
approached in either the hospital or outpatient clinic during a routine visit. One of the
investigators invited the subjects and any siblings meeting the criteria to participate. After
recruitment, the patient population included sixty children, between the ages of five and
twenty-two, who fit within the inclusion and exclusion criteria. The inclusion criteria
included having a diagnosis of either ALL, a type of lymphoma, or a solid tumor; at the
appropriate point in treatment based on diagnosis and treatment regime (see appendix A);
subjects who gave assent according to institutional guidelines and parental consent to
participate. Exclusion criteria included a diagnosis of CNS cancer; a lower extremity
amputation or limb salvage surgery; an antecedent neurological, developmental, or
genetic disorder; or an ICU stay longer than 48 hours in the previous two weeks. The
control population included thirty-six children, between the ages of five and twenty-one,
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who were siblings of the patient population or children of clinical staff at Children’s
Hospitals and Clinics of Minnesota. After completing all the testing, each participant
received a ten-dollar gift card.

Procedures
Initially, general health information was collected through a chart review for the
patient population and a health history form for the control population. The information
gathered from both groups included the following: age, gender, height, weight, leg
length, co-morbid conditions, and current medications. Additionally, cancer type and
treatment parameters were collected by medical record abstraction for the patient
population.
Impairment measures included a neuropathy scale and ankle dorsiflexion range of
motion (ROM) and strength. These impairments were chosen based on previous
literature, which states these impairments have impacts on the functional mobility of
individuals after chemotherapy treatment. 5,6,9 The neuropathy scale used was the
pediatric-modified total neuropathy scale (ped-mTNS), which is a scale adapted by Dr.
Laura Gilchrist for the use in the pediatric population. This scale uses clinical assessment
tools including deep tendon reflexes, pin sensibility, vibration sensation, light touch, and
manual muscle testing.20,21 Based on the score in all five areas, an overall score is
generated. (see appendix B)
Ankle dorsiflexion ROM was measured with subject positioned in prone with the
knee extended and the foot over the edge of the table. The knee extended position has
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been found to correlate best with available ROM of the ankle during heel strike phase of
gait (a point in the gait cycle that the greatest amount of ankle dorsiflexion is required).
When a standardized approach is used by trained clinicians, the inter-rater reliability has
been reported to be high (0.88).22 The last impairment measure was ankle dorsiflexion
strength, which was measured in standard manual muscle testing position. Reliability for
manual muscle testing has been reported to be good (0.63).23
The GaitRITE gait analysis system was used to collect the gait measures used in
this study. This system involves an electronic walkway that contains sensor pads that are
connected to a computer for data acquisition. The spatiotemporal parameters of gait
focused on in this study included velocity, cadence, step length, single limb support,
double limb support, and base of support. The GaitRITE was used instead of
observational gait analysis since the GaitRITE has been proved to be reliable and valid
among a multitude of populations as discussed earlier, whereas; observational gait
analysis has questionable validity and reliability.24,25 Each subject completed two trials
and the gait variables were averaged for the two trials. All subjects were instructed to
walk at their “normal” speed. Additionally, velocity, cadence, and step length were
normalized to account for the varying height differences amongst the participants.
Lastly, the functional measure used was the six minutes walk test (6MWT), which
is a measure of sub-maximal functional capacity and endurance of the cardiorespiratory
system. Guidelines for administration from American Thoracic Society26 were followed.
The 6MWT demonstrated strong concurrent validity to the VO2 max during the treadmill
test and strong test-retest reliability.27 Recently, height-specific reference standards for

9

the 6MWT were constructed using a sample of 1,445 healthy children aged 7 to 16
years.28

Statistical Analysis
After the data collection, the data was entered into an Excel spreadsheet by two
researchers. Two different researchers performed a spot check of the data to ensure
accurate entry and removed extreme values determined to be likely due to measurement
error and subjects with missing data.
In order to account for unequal stature between participants, various methods of
normalization that have been previously established in other studies was investigated.
These methods include scaling data to leg length, height, velocity, and body mass.29 In
literature, Hof discussed non-dimensional forms as methods of normalizing data such as
by leg length. Hof described dividing data by the normalization variable or using ratios to
obtain dimensionless data.29 In addition, a study by Standsfield et al. reported semidimensional and non-dimensional normalized data in a seven year longitudinal study of
gait in 16 children ages 5-12 years old. In this study, the children walked over the
GaitRite system and the researchers collected ground reaction forces, motion data,
weight, height and leg length. Semi-dimensional normalization was used for velocity,
cadence, and step length based on description in the literature. Non-dimensional
normalization was utilized for weight, length and time. The gait data was normalized to
height and leg length. These authors recommended use of non-dimensional normalization
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rather than semi-dimensional for comparing the development of children’s gait
patterns.18,29
Based on the literature stated above, selected gait characteristics including
velocity, cadence, and left and right step length were normalized in order to account for
size differences amongst participants per the protocol described by Strandsfield et al. The
formula used for normalization was (leg length/height) x variable, where the variable was
either velocity, cadence, or step length.18 Stride length was not analyzed for our purposes
as it is not directly addressed in clinic practice.
SPSS version 19 was used for statistical analysis of the results. ANOVA and
MANOVA procedures were used to analyze variance between groups. MANOVA was
used when multiple variables were included in the analysis in order to minimize
experiment-wise error rate. Pearson R correlation was used to verify relationships
between selected variables.
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Chapter IV: RESULTS
Demographics
Table 1 shows the means +/- 1 standard deviation of age and height and
percentage for gender and cancer type as well as the percentages for gender and cancer
type. Based on the MANOVA analysis, no statistical significance difference was found
between the two groups ( >0.05). A MANOVA analysis revealed that there was no
significant difference in age, height, and gender between the cancer and control group.
Table 1. Baseline characteristics of patients with cancer and the control group
Cancer Group (n=60)
Control Group (n=36)
Mean ± 1 SD
Mean ± 1 SD
Age (years)
11.6 ± 4.6
11.2 ± 3.4
Height (cm)
147.4 ± 23.2
149.3 ± 18.7
Gender (%M)
43
53
Diagnosis (%)

48.3
ALL

30.0
Lymph

21.7
ST

NA

Our first hypothesis was that the gait characteristics of children/adolescents with
cancer will differ from children/adolescents without cancer. A MANOVA analysis
using Wilks' Lambda between the cancer (n=60) and the control group (n=36) was run to
determine differences between the groups for the following gait characteristics: mean
normalized velocity, cadence, left and right step length, and right and left base of support,
and single limb support time. The analysis revealed significant differences between the
cancer and control group for mean normalized velocity, cadence and left step length
(p≤.05). Subjects with cancer demonstrated significantly slower walking velocity
(p=.001), decreased cadence (p=.007) and shorter left step length (p=.034) compared to
controls. Mean normalized right step length approached significance at p=.056, however,
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was not statistically significant. In addition, there was no significant difference in mean
left and right base of support and single limb support time between the groups (p≥.05).
This analysis yielded sufficient power at 0.860.

Graph 1 and 2 show the significant differences in mean normalized velocity and cadence
between the cancer and control group (p≤0.05). These graphs demonstrate that subjects
with cancer had significantly reduced velocity and cadence.

Graph 3 shows differences in mean
normalized left and right step length
between the cancer and control group.
Left step length was found to be
significantly different between the
groups (p ≤0.05) and although right step
length approached significance at 0.056,
it was not significant.
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Our second hypothesis was that the gait characteristics of children treated with
different types of chemotherapy regimes will be similar. A MANOVA analysis using
Wilks' Lambda between subjects who received only vincristine (n=22) and those who
received vincristine with intrathecal (IT) methotrexate (n=38) was run to determine
differences between the chemotherapy treatment groups for the following selected gait
characteristics: mean normalized velocity, cadence, left and right step length, and right
and left base of support, and single limb support time. The MANOVA analysis showed
that no significant differences were found in gait characteristics when adding IT
methotrexate to vincristine treatment for normalized velocity, cadence, left and right step
length, and left and right base of support and single limb support time (Wilks'
Lambda=.932; F8-51=.467;p=.873). The power analyses yielded a power of 0.195
suggesting that there was an insufficient sample size to detect a difference between
groups.

Graphs 4 and 5 illustrates the effect of Vincristine and Vincristine with IT Methotrexate
on the mean normalized velocity and cadence in patients with cancer. These graphs show
that no significant differences were found between treatments for these gait variables
(p≥0.05).
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Graph 6 illustrates the effect of
Vincristine and Vincristine with IT
Methotrexate on the mean normalized
left step length. Similarly, there was no
difference in left step length between
the chemotherapy treatment groups
(p≥0.05).

Our third hypothesis was that select neuromuscular impairments will be
significantly related to changes observed in the gait pattern of children with cancer. The
Pearson R correlation analysis was used to determine relationships between impairment
and gait variables. Explored impairment variables included neuropathy, left and right
dorsiflexion strength, and left and right active dorsiflexion range of motion. Explored gait
variables included normalized velocity, cadence, and left and right step length. Other gait
variables such as right and left base of support and single limb support were not included
in the correlation analysis as they were not statistically significant between the cancer and
control groups. Mean normalized cadence was significantly inversely correlated with
mean neuropathy (r= -.280, p ≤.05). Also, mean left dorsiflexion strength was positively
correlated with mean normalized left step length (r=.306, p ≤.05). Lastly, mean right
dorsiflexion strength was significantly positively related to normalized mean right step
length (r=.263, p ≤.05). Based on the correlation analysis we found that patients with
higher neuropathy scores demonstrated lower cadence. In addition, patients with greater
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left and right dorsiflexion strength had longer left step length. No other correlations
between neuromuscular impairments and gait characteristics were statistically significant.

Table 2. Significant Correlations Between Impairments and Gait Characteristics
Gait Variables

Impairments

Velocity

-.100

L DF
Strength
.217

Cadence

-.280*

-.055

-.040

.159

.176

L Step Length

.111

.306*

.263*

-.084

-.093

R Step Length

.149

.246

.218

-.052

-.036

Neuropathy

R DF
Strength
.209

L DF
ROM
.069

R DF
ROM
.058

Table 2 demonstrates the significant correlations between impairments and gait
characteristics. The correlation (r) value is listed between impairment variables and gait
variables. Significant correlations are bolded in the table. * Indicates significance of
p≤ 0.05.

Our fourth hypothesis was that children without cancer will walk farther in six
minutes compared to children with cancer. An ANOVA analysis using Wilks' Lambda
between the cancer (n=60) and the control group (n=36) was run to determine if a
difference existed in the 6 minute walk distance between the groups. The 6 minute walk
distance was chosen for analysis as it is a functional measure of the efficiency of ones'
gait. The analysis revealed significant differences in the distance children were able to
walk in 6 minutes between children with cancer compared to controls (p≤.001). Our
results suggest that patients without cancer walker farther in 6 minutes when compared to
children with cancer.
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Graph 7 demonstrates the 6 minute walk
distance in meters between the cancer and
control group. This graph demonstrates
that patients without cancer walked
farther in 6 minutes when compare to
children with cancer (p≤0.05).

Our fifth hypothesis was that selected gait characteristics will be significantly
related to the distance cancer patients walked in six minutes. Pearson R analysis was used
to determine relationships between gait characteristics and the 6 minute walk distance.
Variables that were included in Pearson R analysis were the 6 minute walk distance, left
and right single limb support and normalized velocity, cadence, and left and right step
length. Significant positive correlations were found between the distance walked in 6
minutes and normalized velocity and step length in cancer patients. Mean normalized
velocity was positively correlated with mean 6 minute walk distance (r=.354, p≤.05).
Mean normalized right step length demonstrated a positive relationship with mean 6
minute walk distance (r=.347, ,p≤.05). Lastly, mean normalized left step length
demonstrated a positive relationship with mean 6 minute walk distance (r=.321, p≤.05).
No other significant correlations were found. These results suggest that with increased
speed and step length (right greater than left), children demonstrated increased walking
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distance in 6 minutes. In addition, we did not find a significant relationship between
single limb support, and normalized cadence with 6 minute walk distance.

Table 3. Significant correlations between selected gait variables and
6 minute walk distance
Significant Correlation Values
Normalized Velocity

.354*

Normalized R Step Length

.347*

Normalized L Step Length

.321*

Table 3 demonstrates significant correlations between selected gait variables and the 6
Minute Walk Distance( p ≤0.05).
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Chapter V: DISCUSSION
The results of the current study indicate children who have gone through a
chemotherapy treatment of vincristine or vincristine with IT methotrexate have impaired
gait characteristics and functional mobility compared to children without cancer.
Significant differences were found both at the impairment and functional levels, with
significant correlations between the two. Children treated with chemotherapy had
significantly slower velocities, decreased cadence and left step length when compared to
the control group, suggesting that chemotherapy has a negative impact on gait
characteristics.
Although differences between the groups were found, no significant results were
found as a function of the type of chemotherapy received within the cancer group. The
addition of IT methotrexate to the vincristine regimen did not significantly affect any of
the children’s gait characteristics. These results are somewhat consistent with what
Hartman and colleagues found in 20068 when investigating the motor performance in
children with cancer and whether this performance was based on cumulative vincristine
dosage. Using the Movement Assessment Battery for Children scale (m-ABC), they
measured differences in 128 children between ages of 4 and 12 who had completed
treatment at least one year prior. Results of that study found no significant differences on
the functional measures between children who received pulses of vincristine and steroids
during treatment compared to those who did not. This literature, in addition to our
results, suggests the addition of IT methotrexate does not further influence the effect on
gait characteristics.
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Investigation into the impact of impairments on gait characteristics in this study
revealed significant associations within the cancer group. As hypothesized, worse
neuropathy was associated with a reduced cadence, as well as stronger left and right
dorsiflexion strength correlated with increased left step length. Comparison of these
results to previous literature found changes in ankle dorsiflexion and peripheral muscle
strength as long-term side effects of chemotherapy treatment in children. A study done
by Hartman and colleagues10 examined these deficiencies in ankle dorsiflexor and wrist
extensor strength and ROM pinch grip, as well as their association with motor
performance. When comparing these impairments to functional measures, ankle
dorsiflexion ROM was not significantly correlated with functional movement on the mABC. Although this study investigated functional movement and not specific gait
characteristics, it was similar to our findings of a lack of correlation between ankle ROM
and gait characteristics.
Another result of this study found children without cancer walked farther
distances in six minutes than those in the cancer group. This was consistent with what
we anticipated and is congruent with the literature Ness and colleagues9 performed that
found walking efficiency was the most common physical performance limitation seen in
cancer survivors, with 46.5% of participants scoring in the lowest 10th percentile,
compared to age, sex, height, and weight matched normative values. While in this
analysis we did not normalize the data for height or gender, the demographic analysis of
the two groups yielded no significant differences. Thus, we feel comfortable that the
differences between groups on the six minute walk distance are due to cancer and
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treatment variables and not height or gender. Overall, these findings demonstrate the
negative impact cancer and chemotherapy have on functional activities such as
community ambulation.
Our final hypothesis studied the impact of gait characteristics on the six-minute
walk test results. Consistent with our prediction, we found that six minute walk distance
was significantly correlated with self-selected “normal” velocity on the GaitRite mat as
well as left and right normalized step lengths for their “normal” walking velocity. Ankle
dorsiflexion strength was positively correlated with step length and step length was also
positively correlated with velocity. These relationships suggest variables such as these
can impact the ability to walk efficiently. It is important to take into consideration,
however, the toxicity chemotherapy has on other systems, such as the cardiovascular and
pulmonary systems, which also affect the distance one can walk in six minutes. The
analysis of the impact of impairments of other body structures and systems on walking
distance is beyond the scope of this study.
Collectively, these outcomes uncover the potential for physical therapy in this
population and suggest therapists should take into consideration the power of improving
ankle dorsiflexion strength and delegating time to perform gait interventions. It is also
important for therapists to examine the barriers to treating this population. A study by
Jones and colleagues19 found the barriers for exercise recommendations by physicians
included not being aware of the benefit in this population and being unsure of referral
options. It is crucial that therapists strive to educate physicians on the available literature
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and potential for physical therapy as well as provide a referral option for cancer
survivors.
The results from this study should be interpreted while taking into consideration
possible limitations. These include a limited number of participants and diagnoses as well
as no intentional age or gender matching between groups at this time. The impairments
and gait characteristics were only measured once, compared to examining the changes
over time. The impact of the two agents vincristine and IT methotrexate were analyzed;
however, children did receive other medications that could potentially impact gait
variables. The GaitRite system was used to measure the gait characteristics and therefore
there was no kinematic record or EMG data to examine. All of these limitations have to
potential to be addressed in follow up studies of this population.
There are many future opportunities for research on this topic. It would be
beneficial to measure the changes in gait characteristics before and after performing the
six-minute walk test in order to evaluate the impact of fatigue on these parameters. It
would also be important to recruit more participants, match the control and cancer group
by age and gender and further evaluate the impact of differing chemotherapy doses of
vincristine and IT methotrexate as well as the influence of other medications. It would be
valuable to track changes in impairments over time and research needs to be conducted to
investigate the impact physical therapy interventions may have on improving gait
characteristics in this population.
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Chapter VI: CONCLUSION
In conclusion, this study gives insight into the impact of chemotherapy on
selected gait characteristics in children and young adults. Physical therapy may benefit
this population by working to improve impairments, gait patterns, and overall function.
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APPENDICES

Diagnosis
ALL
Lymphoma
Hodgkins
Low Risk
Hodgkins
Int/High Risk
Non-Hodgkins
Solid Tumors
Ewings Sarcoma
EwingsSarcoma
/alt protocol
Neuroblastoma

Appendix A: Timing of Measurement
* Indicates Time of Physical Impairment and Motor Performance Measurement
Month 1
2
3
4
5
6
7
8
9
10
Intensive Chemotherapy
*
Maintenance Chemo 2-3 years
Chemotherapy

*

Chemotherapy
Chemotherapy
Chemotherapy
Chemotherapy

Follow-up
*

*

11

Follow-up
Maintenance Chemo
S±
R
S±
R

Chemotherapy

*

Chemotherapy

*

Chemotherapy (up to 1 year)

RhabdomyoChemotherapy
S± Chemotherapy
sarcoma Low risk
R
RhabdomyoChemo
S ± Chemotherapy
sarcoma Int. Risk
R
Wilm’s
S± Chemotherapy
Tumor
R
Wilm’s Tumor
Chemotherapy
S±
Alt. Protocol
R
S = Surgery, R = Radiation

Follow-up
Follow-up
Follow-up

* (or within 1 month of end if treatment > 6 mo)
*

Follow-up
*

*
Chemotherapy

*

Follow-up
Followup
Follow-up

12
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Appendix B:
Pediatric - Modified Total Neuropathy Scale
Sensory Symptoms: ______ (record worst score for the three sensations)
“ Do you have any parts of your body that are tingly, numb (can hardly feel), or hurt?”
______ Tingly ______ Numb ______ Hurt (record number for each)
If yes, “Where you have those feelings?”
0
None
1
Symptoms limited to fingers or toes
2
Symptoms extend to ankles or wrists
3
Symptoms extend to knee or elbow
4
Symptoms above knee or elbow
Functional Symptoms: ______ (record worst score of the three questions)
“Do you have trouble buttoning shirts or tying your shoes?” ______
“Do you have trouble walking such as tripping frequently?”
________
“Do you have trouble going up or down stairs?” _______
If yes to any, “Is it…..(read choices)” and record after each question
0
Not Difficult
1
A little difficult
2
Somewhat difficulty
3
I need help
4
I can’t do that at all
Autonomic Symptoms: _____ (record worst score of the three questions)
“Do you feel dizzy or light-headed when you get up out of bed?”
“Do your hands or feet feel hotter or colder than normal?”
0
Never
1
A little bit
2
Sometimes
3
Very much
4
Almost always
Clinical Testing:
Light Touch Sensation: ______
0
Normal
1
Reduced in fingers/toes
2
Reduced up to wrist/ankle
3
Reduced up to elbow/knee
4
Reduce to above elbow/knee
Semmes
Toes

R
L
Med Mal R
L
Knee
R
L

Semmes
Finger R
L
Wrist R
L
Elb
R
L

Bumps

XXX
XXX
XXX
XXX
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Pin Sensibility: _____
0
1
2
3
4

Normal
Reduced in fingers/toes
Reduced up to wrist/ankle
Reduced up to elbow/knee
Reduce to above elbow/knee

Vibration Sensibility: _______ (worst score)
0
Normal
1
Reduced in fingers/toes
2
Reduced up to wrist/ankle
3
Reduced up to elbow/knee
4
Reduce to above elbow/knee

Toes

R
L
Med Mal R
L
Knee
R
L

Bioesth
/
/
/
/
/
/

R-S TF
Finger R
L
Wrist R
L
Elb
R
L

Bioes
/
/
/
/
/
/

R-S TF

Strength: _____ Worst Score
(MRC Score R / L)
MRC level: Great Toe ___/___ ankle DF___/___ finger abd___/___ wrist ext___/___
0
Normal
1
Mild weakness (MRC 4)
2
Moderate weakness (MRC 3)
3
Severe weakness (MRC 2)
4
Paralysis (MRC 1-0)

Deep Tendon Reflexes: _____ (Achilles, Patellar)
0
Normal
1
Ankle reflex reduced (Achilles +1)
2
Ankle reflex absent (Achilles 0, others +2)
3
Ankle reflex absent, others reduced (Achilles 0, others +1)
4
All reflexes absent (all 0)

